CHCHD2 and CHCHD10 promoted autophagic clearance of protein aggregates via GABARAPs

Two mitochondrial proteins — CHCHD2 and CHCHD10 — have long been linked to several neurodegenerative diseases including Parkinson's, ALS, frontotemporal dementia, and Alzheimer's disease, but exactly how their mutations cause harm was unclear. This study reveals that both proteins play a direct, previously unrecognized role in autophagy, the cellular recycling process that clears out damaged or misfolded proteins before they accumulate into toxic clumps. The researchers found that CHCHD2 and CHCHD10 physically bind to a family of autophagy proteins called GABARAPs, forming a larger complex that also includes the protein C1QBP/p32 and the autophagy-initiating ULK1 machinery. This binding serves a dual purpose: the proteins are themselves cleared via autophagy, and they actively help switch autophagy on. When CHCHD2 was removed or carried a disease-linked mutation (T61I) in human stem-cell-derived dopamine neurons, autophagy initiation stalled. Crucially, restoring CHCHD2 function reduced protein aggregates in cells and lowered toxic α-synuclein levels in the striatum of mice — the brain region most affected in Parkinson's disease. The findings reframe CHCHD2 and CHCHD10 as both targets and activators of the autophagy system, opening a new therapeutic angle for diseases that currently have no disease-modifying treatments.

• CHCHD2, CHCHD10, and C1QBP/p32 form a quaternary complex with ATG8-family proteins, binding preferentially to the GABARAP subfamily rather than LC3s; disease-associated mutations in CHCHD2 and CHCHD10 showed varied (reduced or altered) interaction with ATG8s compared with wild-type proteins.
• Transient knockdown of CHCHD2 and genetic ablation or T61I mutation in human iPSC-derived dopaminergic neurons each caused measurable defects in autophagy initiation, demonstrating that CHCHD2 loss-of-function is sufficient to impair the early autophagy cascade in a disease-relevant cell type.
• CHCHD2 overexpression reduced protein aggregate burden in cultured cells and decreased toxic SNCA/α-synuclein species in the mouse striatum in vivo, directly linking CHCHD2-mediated autophagy activation to clearance of a hallmark neurodegenerative pathology.

This is a mechanistic cell and molecular biology study combining co-immunoprecipitation, proximity-ligation, and structural interaction assays to map the CHCHD2–CHCHD10–C1QBP–ATG8 complex. Functional autophagy assays were performed in mammalian cell lines with siRNA knockdown and in human iPSC-derived dopaminergic neurons carrying CRISPR-engineered CHCHD2 knockout (CHCHD2⁻/⁻) or the Parkinson-linked point mutation CHCHD2^T61I. In vivo validation used mouse striatal injections to assess SNCA/α-synuclein aggregate clearance following CHCHD2 modulation; specific animal numbers and temporal follow-up windows are not detailed in the abstract.

The in vivo component is limited to α-synuclein clearance in the mouse striatum and does not yet demonstrate whether CHCHD2/CHCHD10 modulation rescues neuronal survival or behavioral deficits in a full Parkinson's or ALS animal model. The study does not resolve whether the autophagy-activating function of CHCHD2/CHCHD10 is entirely GABARAP-dependent or whether parallel mitochondrial stress-signaling pathways contribute. Most mechanistic data were generated in overexpression or knockdown systems; the physiological stoichiometry of the CHCHD2–CHCHD10–C1QBP–GABARAP complex in neurons remains to be established. It is also unclear whether all disease-associated mutations that show impaired ATG8 binding uniformly reduce autophagic flux, as mutations showed 'varied' interactions, warranting allele-by-allele functional analysis.

This study extends the corpus on selective autophagy in neurodegeneration by defining a new receptor-like function for mitochondria-associated proteins at the GABARAP scaffold, a mechanistic layer that parallels the lysophagy pathway described in [§38], where selective ATG8 engagement likewise protects neurons from proteotoxic stress. The CHCHD2/CHCHD10 findings also parallel [§80], which characterizes irisin-integrin-mediated phagocytic clearance of α-synuclein — both studies converge on reducing toxic SNCA species in brain tissue through distinct upstream mechanisms, providing complementary therapeutic angles. The demonstration that autophagy initiation fails specifically in iPSC-derived dopaminergic neurons harboring disease mutations contextualizes work in [§129], which similarly links a transcription factor (MITF) to autophagy competence in a specialized, post-mitotic cell type, reinforcing that cell-type-specific autophagy regulators are a recurring theme across degenerative diseases. Together, these articles build a picture in which maintaining autophagy flux — whether through mitochondrial scaffolding proteins, lysosomal quality control, or phagocytic receptors — is a shared, targetable node in neurodegeneration.

• Mammalian Lysophagy: mechanisms and pathophysiological implications
  Both studies investigate selective autophagy pathways mediated by GABARAP/ATG8 family proteins; comparing them clarifies how different cargo-receptor systems (CHCHD2/10 for protein aggregates vs. lysophagy receptors for damaged lysosomes) use the same ATG8 scaffold to protect neurons from proteotoxic stress.
• Irisin-integrin αV/β5 coupling of α-synuclein phagocytosis and clearance
  Both articles report in vivo reduction of toxic α-synuclein species in brain tissue, but through entirely different upstream mechanisms (CHCHD2-driven autophagy vs. irisin-integrin phagocytosis), making direct comparison useful for gauging which pathway offers a more tractable therapeutic target in Parkinson's disease.
• MITF is essential for autophagy in the retinal pigment epithelium
  Both studies demonstrate that a single gene's loss is sufficient to block autophagy initiation in a specialized post-mitotic cell type (dopaminergic neurons vs. retinal pigment epithelium), highlighting cell-type-specific autophagy dependencies with implications for tissue-targeted therapy design.
• FOXO transcription factors in Alzheimer's Disease: balancing neuroprotection and neuronal degeneration
  FOXO transcription factors regulate autophagy gene expression in Alzheimer's disease neurons, providing a transcriptional regulatory counterpart to the post-translational, protein-complex mechanism described here; comparing the two illuminates upstream vs. downstream control points within the same neuroprotective pathway.